RBC Capital analyst Brian Abrahams maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Sector Perform and raises the price target from $15 to $18.
‘GM temporarily stops making the Chevy Bolt after latest recall’ -The Verge
https://www.theverge.com/2021/8/30/22648922/gm-chevy-bolt-ev-production-halt-recall-fire-risk